A-FABP—A Biomarker Associated With the Metabolic Syndrome and/or an Indicator of Weight Change?
Version of Record online: 6 SEP 2012
2008 North American Association for the Study of Obesity (NAASO)
Volume 16, Issue 8, pages 1838–1842, August 2008
How to Cite
Engl, J., Ciardi, C., Tatarczyk, T., Kaser, S., Laimer, M., Laimer, E., Weiss, H., Aigner, F., Molnar, C., Tilg, H., Patsch, J. R. and Ebenbichler, C. F. (2008), A-FABP—A Biomarker Associated With the Metabolic Syndrome and/or an Indicator of Weight Change?. Obesity, 16: 1838–1842. doi: 10.1038/oby.2008.273
- Issue online: 6 SEP 2012
- Version of Record online: 6 SEP 2012
- Received May 16, 2007; Accepted August 07, 2007
Objective: Adipocyte fatty acid-binding protein (A-FABP) is a plasma biomarker recently associated with the metabolic syndrome. The aim of these studies was to investigate changes of A-FABP during profound weight loss induced by laparoscopic adjustable gastric banding (LAGB).
Methods and Procedures: In study one, 29 severely obese female subjects were examined before and 1 year after surgical treatment. A subgroup of 10 patients was investigated in 3-month intervals. Metabolic parameters were determined using standard methods, and A-FABP was detected using a commercially available enzyme-linked immunosorbent assay.
Results: Mean weight loss after 1 year was 24.9 kg (P < 0.001), mainly due to a decrease in fat mass. Metabolic parameters improved substantially. However, serum A-FABP remained stable. In study two, a subgroup of 10 patients was examined quarterly to determine the time course of A-FABP changes. Quarterly measurements of serum A-FABP were significantly higher than baseline levels with the highest A-FABP value after the first 3 months, where patients had highest weight loss.
Discussion: Our results in study one show that A-FABP serum levels are positively associated with body weight and fat mass. However, 1 year after pronounced weight loss A-FABP levels remained unchanged. In study two, time course analyses revealed maximum increase of serum A-FABP in parallel to highest weight loss, which allows to suppose that A-FABP is not only a biomarker of the metabolic syndrome in the steady state, but also a marker of weight changes in dynamic situations.